Recent Advances in Frailty Assessment: A High-Yield MRCP PACES Update

Why Frailty Matters in MRCP PACES

Frailty has become one of the most heavily examined topics in MRCP PACES, appearing across Stations 1, 3, and particularly Station 5 consultations. With the UK's ageing population and the integration of frailty into national guidelines (NICE, BGS, NHS England), examiners increasingly expect candidates to demonstrate a senior-level understanding of frailty assessment, its prognostic implications, and its impact on clinical decision-making. Recent research has transformed how we conceptualise, identify, and manage frailty—knowledge that can set you apart in the exam.

The 2024–2025 Research Landscape: What Has Changed?

1. Electronic Frailty Index (eFI v2) — Validated at Scale

The Electronic Frailty Index version 2 (eFI v2), developed by the University of Leeds and validated in over 2.5 million UK primary care records, has now been endorsed by NHS England for population-level identification. Unlike the original eFI, v2 incorporates 40 cumulative deficit variables drawn from routine GP electronic health records.

Key exam-relevant points:

• eFI categories: Fit (≤0.08), Mild (0.09–0.13), Moderate (0.14–0.24), Severe (≥0.25)

• Strong predictive validity for mortality, hospitalisation, and care home admission within 1–3 years

• Now integrated into the NHS England Supported Discharge and Ageing Well programmes

• Limitation: eFI cannot be used alone—it must complement clinical assessment, not replace it

PACES Tip: If an examiner asks how you would identify frail patients in your trust, mentioning the eFI alongside the Clinical Frailty Scale (CFS) demonstrates awareness of both population-level and bedside tools.

2. Clinical Frailty Scale (CFS): Mounting Evidence for Acute Settings

The Rockwood Clinical Frailty Scale has accumulated substantial new evidence supporting its use in acute hospital settings:

• A 2024 multicentre UK cohort study (n > 14,000) confirmed that CFS ≥5 independently predicts 30-day mortality, length of stay, and new care home admission in patients aged ≥75 admitted as emergencies

• CFS has now been validated in critical care (FRAIL-ACTIVE study) and post-operative populations

• The CFS has been adopted as a mandatory screening tool in many NHS trusts for all admissions ≥65 years

For PACES, you should be able to:

• Assign a CFS score at the bedside with justification

• Explain how CFS influences decisions around ceiling of care, resuscitation status, and discharge planning

• Discuss the important caveat: CFS should not be applied to patients with stable single-system disabilities (e.g., multiple sclerosis, cerebral palsy) without contextual adjustment

3. Comprehensive Geriatric Assessment (CGA): Evidence Reinforces Its Value

A 2023 Cochrane review update reaffirmed that CGA reduces mortality (OR 0.83), reduces hospital admission, and improves the likelihood of patients living at home at follow-up. Newer research has focused on:

• CGA in surgical populations: The PREOP-CEA trial showed pre-operative CGA reduced post-operative complications by 21% in patients ≥65 undergoing elective surgery

• CGA in oncology: The CARG and CRASH scoring systems for chemotherapy toxicity prediction in older adults with cancer are now recommended by ASCO and SIOG

• Virtual CGA models: Telemedicine-delivered CGA during and post-COVID has shown non-inferior outcomes for community-dwelling older adults

4. Frailty Reversibility — A Paradigm Shift

Perhaps the most exciting recent development is growing evidence that frailty is potentially reversible:

• A 2024 systematic review and meta-analysis (n > 5,000) demonstrated that structured resistance training and protein supplementation improved frailty status in 28–40% of pre-frail and frail older adults over 6–12 months

• The FPN (Frailty Prevention Network) UK pilot showed that multidomain interventions (exercise, nutrition, medication review, social engagement) improved CFS scores in community-dwelling adults by ≥1 category in 35% of participants

• Sarcopenia-specific interventions using the AWGS 2024 criteria have shown particular benefit in patients with coexisting frailty and sarcopenia

PACES Tip: Examiners may probe whether you consider frailty a fixed or dynamic state. Referencing the reversibility evidence demonstrates contemporary, evidence-based thinking.

5. Frailty in Specific Conditions — Condition-Specific Frailty Research

Recent research has explored frailty in specific clinical contexts that frequently appear in PACES:

Applying Frailty Research in PACES Stations

Station 5 (Consultation)

A common scenario involves an older patient with multiple comorbidities presenting with a new problem (e.g., falls, delirium, functional decline). Here is how to integrate recent frailty evidence:

During the encounter:

1. Ask about functional baseline — walking aids, ADLs, IADLs

2. Screen for frailty — use CFS implicitly or explicitly

3. Assess for reversible contributors — medications (anticholinergics, polypharmacy), mood, nutrition, social isolation

4. Discuss prognosis honestly — if relevant, use frailty as part of a shared decision-making conversation

During the discussion with the examiner:

1. Present the patient's CFS score with justification

2. Discuss how frailty modifies your differential diagnosis and investigation plan

3. Propose a CGA-informed management approach

4. Reference relevant national guidance (NICE NG56 for transition between inpatient settings, BGS Fit for Frailty)

Stations 1 and 3 (Physical Examinations)

In patients with neurological or musculoskeletal presentations, demonstrating awareness of sarcopenia screening (grip strength, gait speed, SARC-F questionnaire) can earn additional marks. The European Working Group on Sarcopenia in Older People (EWGSOP2) criteria are increasingly expected knowledge.

High-Yield Frailty Facts for the Exam

1. Frailty ≠ old age. Frailty is a distinct clinical syndrome characterised by decreased physiological reserve and increased vulnerability to stressors.

2. CFS is bedside-friendly; eFI is population-level. Know when to use each.

3. Frailty is a vital sign. The BGS now recommends routine frailty identification for all patients ≥65 in acute settings.

4. Frailty modifies treatment decisions. Be prepared to discuss how it influences anticoagulation in AF, cancer treatment intensity, and surgical risk.

5. Frailty is potentially reversible. This is a paradigm-shifting concept that examiners appreciate.

Key Takeaways

Recent research has fundamentally shifted frailty from a descriptive label to a measurable, modifiable, and clinically actionable parameter. For MRCP PACES candidates, this means:

• You must be able to assess frailty at the bedside (CFS)

• You should understand how frailty modifies management across multiple specialties

• You should be able to discuss evidence-based interventions (CGA, resistance training, medication review)

• You should recognise frailty as a dynamic state with potential for improvement

Mastering this evolving evidence base will not only strengthen your PACES performance but also prepare you for the realities of modern geriatric-inclusive internal medicine practice.

Have you encountered frailty scenarios in your PACES practice? What challenges do you face in integrating frailty assessment into time-limited consultations? Share your experience and keep refining your approach.

Further Reading:

• NHS England. Using the Electronic Frailty Index (eFI v2). 2024

• NICE Guideline NG56. Transition Between Inpatient Hospital Settings and Community or Care Home Settings. Updated 2024

• British Geriatrics Society. Fit for Frailty. 2023 Update

• Dent E et al. Frailty in older adults. Lancet 2024 (forthcoming review)

• AWGS 2024 Consensus. Asian Working Group for Sarcopenia. J Am Med Dir Assoc 2024